Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
67
GLUE Quote, Financials, Valuation and Earnings
Last price:
$17.24
Seasonality move
:
6.72%
Day range:
$16.57 - $17.63
52-week range:
$3.50 - $17.63
Dividend yield:
0%
P/E ratio:
56.52x
P/S ratio:
7.35x
P/B ratio:
4.57x
Volume:
659.2K
Avg. volume:
1M
1-year change:
86.8%
Market cap:
$1.1B
Revenue:
$75.6M
EPS (TTM):
$0.31
Analysts' Opinion
-
Consensus RatingMonte Rosa Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $17.20, Monte Rosa Therapeutics, Inc. has an estimated downside of -0.35% from its current price of $17.26.
-
Price Target UpsideAccording to analysts, the highest upside price target is $20.00 representing 15.88% upside increase from its current price of $17.26.
Fair Value
-
According to the consensus of 6 analysts, Monte Rosa Therapeutics, Inc. has -0.35% downside to fair value with a price target of $17.20 per share.
GLUE vs. S&P 500
-
Over the past 5 trading days, Monte Rosa Therapeutics, Inc. has overperformed the S&P 500 by 7.82% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Monte Rosa Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Monte Rosa Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Monte Rosa Therapeutics, Inc. reported revenues of $12.8M.
Earnings Growth
-
Monte Rosa Therapeutics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Monte Rosa Therapeutics, Inc. reported earnings per share of -$0.33.
Enterprise value:
772.8M
EV / Invested capital:
2.70x
Price / LTM sales:
7.35x
EV / EBIT:
90.81x
EV / Revenue:
4.26x
PEG ratio (5yr expected):
--
EV / Free cash flow:
5.33x
Price / Operating cash flow:
9.20x
Enterprise value / EBITDA:
45.89x
Gross Profit (TTM):
$173.2M
Return On Assets:
5.33%
Net Income Margin (TTM):
11.54%
Return On Equity:
8.6%
Return On Invested Capital:
7.34%
Operating Margin:
-258.26%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $15M | $181.5M | $9.2M | $12.8M | |
| Gross Profit | -$7.1M | $7.1M | $173.2M | $7.1M | $10.7M | |
| Operating Income | -$140.9M | -$129M | $8.5M | -$26.5M | -$33M | |
| EBITDA | -$133.9M | -$121.1M | $16.8M | -$24.4M | -$30.9M | |
| Diluted EPS | -$2.69 | -$1.83 | $0.31 | -$0.29 | -$0.33 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $370.5M | $295.2M | $182.9M | $251.2M | $401.8M | |
| Total Assets | $384M | $357.6M | $252.1M | $315.1M | $459.8M | |
| Current Liabilities | $12.7M | $21.8M | $22.6M | $41.6M | $61.4M | |
| Total Liabilities | $14.7M | $66.5M | $67.6M | $109.6M | $214M | |
| Total Equity | $369.3M | $291.1M | $184.5M | $205.5M | $245.8M | |
| Total Debt | -- | $42.6M | $43.5M | $40.1M | $35.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$97.4M | -$57.3M | $149.1M | -$21M | $100.4M | |
| Cash From Investing | $20.6M | $741K | -$67.7M | $37.7M | $38.1M | |
| Cash From Financing | $22.8M | $123.5M | $1.3M | $15K | $348K | |
| Free Cash Flow | -$122M | -$62.8M | $145M | -$21.4M | $99.8M | |
GLUE
Sector
Market Cap
$1.1B
$28.4M
Price % of 52-Week High
97.9%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-0.11%
-1.32%
1-Year Price Total Return
86.8%
-22.19%
Beta (5-Year)
--
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$16.16
200-day SMA
Buy
Level
$6.72
Bollinger Bands (100)
Buy
Level
4.54 - 12.46
Chaikin Money Flow
Buy
Level
8.9M
20-day SMA
Buy
Level
$14.75
Relative Strength Index (RSI14)
Buy
Level
73.34
ADX Line
Buy
Level
44.3
Williams %R
Sell
Level
-7.8891
50-day SMA
Buy
Level
$11.80
MACD (12, 26)
Buy
Level
1.38
25-day Aroon Oscillator
Buy
Level
84
On Balance Volume
Neutral
Level
125.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.0473)
Sell
CA Score
(Annual)
Level (-1.1794)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (1.7006)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Monte Rosa Therapeutics, Inc. operates as a biotechnology company, which engages in the developing of precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.
Stock Forecast FAQ
In the current month, GLUE has received 5 Buy ratings 1 Hold ratings, and 0 Sell ratings. The GLUE average analyst price target in the past 3 months is $17.20.
-
Where Will Monte Rosa Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Monte Rosa Therapeutics, Inc. share price will drop to $17.20 per share over the next 12 months.
-
What Do Analysts Say About Monte Rosa Therapeutics, Inc.?
Analysts are divided on their view about Monte Rosa Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Monte Rosa Therapeutics, Inc. is a Sell and believe this share price will rise from its current level to $13.00.
-
What Is Monte Rosa Therapeutics, Inc.'s Price Target?
The price target for Monte Rosa Therapeutics, Inc. over the next 1-year time period is forecast to be $17.20 according to 6 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is GLUE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Monte Rosa Therapeutics, Inc. is a Buy. 5 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GLUE?
You can purchase shares of Monte Rosa Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Monte Rosa Therapeutics, Inc. shares.
-
What Is The Monte Rosa Therapeutics, Inc. Share Price Today?
Monte Rosa Therapeutics, Inc. was last trading at $17.24 per share. This represents the most recent stock quote for Monte Rosa Therapeutics, Inc.. Yesterday, Monte Rosa Therapeutics, Inc. closed at $17.26 per share.
-
How To Buy Monte Rosa Therapeutics, Inc. Stock Online?
In order to purchase Monte Rosa Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get GLUE Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GLUE
Sector
P/E ratio
56.52x
23.66x
PEG ratio
--
-0.01x
P/B ratio
4.57x
1.84x
Price / LTM sales
7.35x
1.60x
Growth Metrics
GLUE
Sector
Revenue growth
38.54%
4.85%
Earnings growth
-12.99%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.35
-$0.20
Profitability
GLUE
Sector
Profitability FY 2024
$67.5M
$3.6M
Return on invested capital
7.34%
-30.98%
Return on assets
5.33%
-27.62%
Return on equity
8.6%
-36.69%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
19
Estimated Next Earnings Date
Feb
5
Balance Sheet
GLUE
Sector
Total cash
$391.3M
$27.2M
Short term investments
$147.9M
$25.7M
Total assets
$438.7M
$79.9M
Long term debt
$35.9M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
44
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
